A federal court in Louisiana recently ordered Takeda Pharmaceutical Company and Eli Lilly & Co., the makers of the popular diabetes drug Actos, to pay patients $9 billion in damages for hiding the risks associated with taking the drug.
Takeda, a Japanese based company, is required to pay $6 billion and their partner Eli Lilly & Co. is required to pay $3 billion. However, according to an agreement between the manufacturers Takeda will most likely be paying Eli Lilly’s share.
While the $9 billion award is the seventh largest in US history, it is likely that the damages will be reduced upon challenges and appeals by the makers of Actos.
More Money for Patient’s Suffering, More Trouble for Actos Makers.
The Louisiana jury was the fourth to rule that Takeda marketed Actos knowing it could cause cancer. They ruled Takeda failed to warn doctors and consumers that about the risk associated with taking the drug. In a 12 month period two state juries, in Maryland and California, ordered Takeda to pay $8.2 million to Actos users.
In addition to the federal lawsuits, Takeda and Lilly are facing considerable claims in state courts. In Illinois Takeda and Lilly are facing over 3,400 cases. In Las Vegas, two women diagnosed with bladder cancer are asking for over $1 billion in damages. In all these cases Actos is blamed for giving the patient cancer.
FREE Actos Case Review
If you or a loved one took Actos and have been diagnosed with cancer you could be owed substantial compensation.
Actos Makers Hid the Truth About Dangers
Takeda has done little to address the concerns over Actos’s potential to cause cancer. They are accused of actively misleading regulators about the dangers of Actos.
Takeda did not provied warnings about the potential of Actos to cause cancer until 2011, 12 years after the drug came on the market and 7 years after experts linked it to causing bladder cancer.
Attorneys for patients claim Takeda waited to warn users of the dangers of Actos because it was the company’s number one selling drug. In fact, Actos was the most popular diabetes drug on the market.
Takeda is also accused of destroying documents describing the development, sales and marketing of Actos prior to discovery.